Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.

OBJECTIVE: To further define the safety and efficacy of recombinant human interleukin 1 receptor antagonist (rhIL-1ra) in the treatment of sepsis syndrome. STUDY DESIGN: Randomized, double-blind, placebo-controlled, multicenter, multinational clinical trial. POPULATION: A total of 893 patients with...

全面介紹

書目詳細資料
Main Authors: Fisher, C, Dhainaut, J, Opal, S, Pribble, J, Balk, R, Slotman, G, Iberti, T, Rackow, E, Shapiro, M, Greenman, R
格式: Journal article
語言:English
出版: 1994